David W. J. Mcgirr Sells 3,000 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) Director David W. J. Mcgirr sold 3,000 shares of the stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $73.27, for a total value of $219,810.00. Following the completion of the sale, the director now directly owns 97,723 shares of the company's stock, valued at approximately $7,160,164.21. This trade represents a 2.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Insmed Trading Up 1.2%

INSM stock traded up $0.88 during trading on Friday, hitting $73.62. The company had a trading volume of 1,558,246 shares, compared to its average volume of 2,072,473. Insmed Incorporated has a 52-week low of $55.74 and a 52-week high of $84.91. The firm has a market capitalization of $13.41 billion, a P/E ratio of -13.17 and a beta of 0.80. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The company has a 50 day simple moving average of $69.28 and a 200-day simple moving average of $73.04.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. During the same period last year, the firm earned ($1.06) earnings per share. Insmed's revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, research analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Stifel Nicolaus decreased their price objective on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research note on Friday, February 21st. JPMorgan Chase & Co. increased their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a research note on Friday, February 7th. Guggenheim reiterated a "buy" rating and issued a $101.00 price objective on shares of Insmed in a research note on Tuesday, February 25th. Jefferies Financial Group assumed coverage on shares of Insmed in a research note on Tuesday, May 13th. They issued a "buy" rating and a $105.00 price objective for the company. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $100.00 price objective on shares of Insmed in a research note on Wednesday, March 19th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Insmed currently has a consensus rating of "Moderate Buy" and an average target price of $96.73.

Institutional Trading of Insmed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Insmed by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock worth $1,393,675,000 after purchasing an additional 49,149 shares in the last quarter. Darwin Global Management Ltd. lifted its stake in Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after purchasing an additional 2,463,261 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Insmed by 1.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company's stock worth $985,938,000 after purchasing an additional 219,131 shares in the last quarter. Capital International Investors raised its holdings in Insmed by 9.1% during the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock worth $491,357,000 after purchasing an additional 593,206 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Insmed by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock worth $282,243,000 after acquiring an additional 273,759 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.